Corcept Therapeutics Incorporated
CORT Healthcare Biotechnology
Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024. In the quarter to June 2026, revenue grew 31.7%, EPS grew 21.2% and free cash flow fell 29.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
Follow CORT
Corcept Therapeutics Incorporated (CORT) Altman Z-score
Corcept Therapeutics Incorporated's Altman Z-score for fiscal 2025 is 14.11, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 14.11 | (8.00) |
| FY2024 | 22.11 | 1.59 |
| FY2023 | 20.51 | 1.65 |
| FY2022 | 18.86 | (12.89) |
| FY2021 | 31.75 | (8.15) |
| FY2020 | 39.90 | 17.38 |
| FY2019 | 22.52 | (5.30) |
| FY2018 | 27.82 | (14.59) |
| FY2017 | 42.41 | 29.03 |
| FY2016 | 13.37 | 11.32 |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.38 | — | 0.46 | |
| Retained earnings / total assets | 0.77 | — | 1.08 | |
| EBIT / total assets | 0.05 | — | 0.18 | |
| Market value of equity / total liabilities | 19.14 | — | 11.48 | |
| Sales / total assets | 0.91 | — | 0.91 | |
| Altman Z-score | Safe zone | 14.11 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 8.97 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| TECH Bio-Techne Corp compare | 15.5× |
| CORT Corcept Therapeutics Incorporated | 14.1× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 10.5× |
| BMRN BioMarin Pharmaceutical Inc. compare | 5.7× |
| HALO Halozyme Therapeutics, Inc. compare | 3.5× |
| JAZZ Jazz Pharmaceuticals PLC compare | 1.4× |
| SMMT Summit Therapeutics PLC compare | 0.9× |
| BBIO BridgeBio Pharma, Inc. compare | −3.5× |
| IBRX ImmunityBio, Inc. compare | −10.2× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets